The advent of next-generation sequencing has changed genetic diagnostics, allowing clinicians to test concurrently for phenotypically overlapping conditions such as Alzheimer's disease (AD) and frontotemporal dementia (FTD). However, to interpret genetic results, clinicians require an understanding of the benefits and limitations of different genetic technologies, such as the inability to detect large repeat expansions in such diseases as C9orf72-associated FTD and amyotrophic lateral sclerosis. Other types of mutations such as large deletions or duplications and triple repeat expansions may also go undetected. Additionally, the concurrent testing of multiple genes or the whole exome increases the likelihood of discovering variants of unknown significance. Our goal here is to review the current knowledge about the genetics of AD and FTD and suggest up-to-date guidelines for genetic testing for these dementias. Despite the improvements in diagnosis due to biomarkers testing, AD and FTD can have overlapping symptoms. When used appropriately, genetic testing can elucidate the diagnosis and specific etiology of the disease, as well as provide information for the family and determine eligibility for clinical trials. Prior to ordering genetic testing, clinicians must determine the appropriate genes to test, the types of mutations that occur in these genes, and the best type of genetic test to use. Without this analysis, interpretation of genetic results will be difficult. Patients should be counseled about the benefits and limitations of different types of genetic tests so they can make an informed decision about testing.
Alzheimer's disease and frontotemporal dementia are two dementias that can overlap clinically and both can be caused by autosomal dominant gene mutations.
Genetic testing in the context of neurodegenerative diseases has the potential to elucidate the diagnosis and provide important information for the family, as well as determine eligibility for clinical trials. However, it must be used appropriately to interpret results correctly.
We suggest up-to-date guidelines for genetic testing for these dementias to assist clinicians in determining the appropriate genes to test, the types of mutations that occur in these genes, and the best type of genetic test to use in different situations.
Introduction
Advances in genetic technology have greatly reduced the cost of genetic testing and enabled rapid massively parallel analysis of genes and, as a result, produced significant developments in diagnostics and therapeutics. However, the efficacious use of this 'next-generation sequencing' (NGS) requires awareness of its limitations. Here we focus on how NGS technology has changed genetic testing for Alzheimer's disease (AD) and frontotemporal dementia (FTD; also known as frontotemporal degeneration), two dementias that can overlap clinically. The goal of this paper is to provide physicians and genetic counselors updated guidelines for how and when to order genetic testing for AD and FTD. A PubMed literature search was used to review the most current information about AD and FTD genetics. We used this information to develop an algorithm for best practices for genetic testing of these diseases.
Alzheimer's Disease (AD)
Approximately 1% of all AD is caused by mutations in autosomal dominant genes [1, 2] . A significantly larger number of cases demonstrate family clustering with both early-(EOAD) and late-onset AD (LOAD) in the same family. The heritability of AD is between 60 and 80% [2, 3] , but many of the genetic mechanisms behind AD have yet to be elucidated.
Autosomal Dominant AD
The genetics of autosomal dominant AD is well-described with three predominant genes identified. Mutations in the presenilin 1 gene (PSEN1) account for about 80% of autosomal dominant cases. Mutations in the presenilin 2 gene (PSEN2) are quite rare, except in families of Volga German ancestry, accounting for only 5% of cases. About 15% of autosomal dominant cases are due to mutations in the amyloid precursor protein gene (APP) [3] . More than 200 mutations have been described in PSEN1, with the majority being missense mutations, but also small duplications and deletions and larger deletions. The median age of onset in PSEN1 mutation carriers is 43 years, with the great majority occurring before the age of 60 years [4] . Approximately 16 mutations have been reported in PSEN2 according to the AD and FTD Mutation Database (http://www.molge n.ua.ac.be/ admut ation s/) [5] . Onset is variable, usually between the ages of 40 and 70 years. PSEN2 mutations have incomplete penetrance [6] . More than 50 different mutations (including small deletions as well as duplications) have been reported in APP, with an age of onset between 45 and 60 years [6] . Whereas missense mutations in APP are fully penetrant, duplications show incomplete penetrance [6] . The phenotype conferred by these autosomal dominant mutations include the classic amnestic presentation, frontal variant AD with behavioral changes resembling FTD, logopenic primary progressive aphasia (PPA), spastic paraparesis, myoclonus, seizures, and parkinsonism [6, 7] .
Non-Autosomal Dominant AD
Sporadic AD also has a strong genetic component. The apolipoprotein E gene (APOE) is associated with a significant risk of both EOAD and LOAD. Of the three common APOE alleles (ε2, ε3, and ε4), ε4 is associated with a dosedependent increased risk of AD. In Caucasians, the relative risk for ε4 heterozygotes is 3-fold and for homozygotes it is about 15-fold [6] . Dose-dependent lowering of the age of onset is also associated with ε4 [8] .
Relative risk differs across ethnicities [8] . ε4 is also associated with an increased risk of cardiovascular disease [9] . In contrast, ε2 confers a small degree of protection against AD [6] . Because APOE is neither necessary nor sufficient to cause AD, genetic testing of APOE is not recommended [10] .
APOE ε4-associated risk accounts for 20-70% of the overall non-Mendelian AD risk [8] . Genome-wide association studies (GWAS) and whole-exome sequencing (WES) studies have uncovered additional moderate-risk genes. An autosomal dominant mutation in ABCA7 (ATP binding cassette subfamily A member 7 gene) was found in a Belgian late-onset family [11] , but ABCA7 variants have also been associated with an increased risk in African Americans that equals the risk of APOE [12] . Risk variants in SORL1 (sortilin related receptor 1 gene) were found in both EOAD [13] and LOAD [6] . TREM2 (triggering receptor expressed on myeloid cells 2 gene) variants may increase risk of AD significantly [14, 15] .
Small-Effect Genes
GWAS and WES have also identified many loci associated with LOAD risk, with wide replication for at least 20 loci. These include genes involved in the neural-immune system (e.g., CLU, CR1, ABCA7, TREM2), synaptic function (e.g., PICALM and NIN1), endocytosis (PICALM, BIN1, SORL1), and lipid metabolism (APOE, CLU, ABCA7) [3] . With the majority of LOAD risk odds ratios being between 1.1 and 1.3, there is currently little clinical value for a multigene prediction score outside of selection of clinical trial participants [16] . Additionally, several rare variants in APP (p.Ala673Thr, rs63750847) and others in PSEN1 would need to be factored in assessing overall risk [6, 17] . Other types of genetic variations may also contribute to LOAD risk, including polymorphisms in the promotors of PSEN1 [18] [19] [20] , copy number variants (CNVs) [21] , and variants in non-coding areas of the genome [6] . While genetic risk variants are very important for research, at the present time, individuals with LOAD should be counseled that, in all probability, genetic testing has no clinical significance.
Frontotemporal Dementia (FTD)
FTD accounts for approximately 10% of all dementias [22] . Unlike the universality of AD pathology with its amyloid plaques and hyperphosphorylated tau tangles, FTD has three underlying pathologies: approximately 40% have tau pathology, approximately 50% have TAR DNA-binding protein 43 (TDP-43) pathology, and about 10% have fused in Sarcoma (FUS) pathology [23] . FTD has two main symptom presentations: behavioral variant FTD (bvFTD), manifesting as behavioral and personality change, and PPA, which is further subdivided into non-fluent aphasia (nfPPA), semantic variant FTD (svFTD), and logopenic PPA (usually with underlying AD pathology) [24, 25] .
FTD Genetics
FTD is highly heritable, with 30-50% of cases having a family history of FTD or related disease, of which 10-20% is autosomal dominant [3] . Three major genes contribute to the autosomal dominant cases: MAPT (microtubule-associated protein tau gene), GRN (granulin precursor gene), and C9orf72 (chromosome 9 open reading frame 72 gene) and mutations are listed in the AD and FTD mutation database (http://www.molge n.vib-ua.be/FTDMu tatio ns) [5, 26] . Pathogenic and risk variants have been reported at much lower frequencies in several additional genes including TAR-DBP (the gene encoding TDP-43) [27] , VCP [28] , CHMP2B (charged multivesicular body protein 2B gene) [29] , ITM2B [30] , TBP [30] , DCTN1 [31] , SQSTM1 (sequestosome 1 gene) [32] , TREM2 [33] , UBQLN2 [34] , CHCHD10 [35] , and TBK1 (TANK binding kinase 1 gene) [26, 36] . The cumulative frequency of these genes accounts for less than 5% of all FTD [30] . However, founder effects may increase the prevalence of individual genes in certain populations (in Belgium TBK1 has been reported as the third most common FTD risk gene) [36] .
MAPT was the first gene associated with FTD, originally known as frontotemporal dementia with parkinsonism linked to chromosome 17 or FTDP-17 [37] . MAPT accounts for 10-20% of autosomal dominant cases depending on the population and, to date, more than 40 different pathogenic variants, mostly in exons 1 and 9-13, have been reported in this gene according to the AD and FTD Mutation Database (http://www.molge n.vib-ua.be/FTDMu tatio ns) [5] . One rare low-penetrance variant in exon 7, p.A152T, has been shown to increase the risk for both FTD and AD and other neurodegenerative diseases [38, 39] . Very few sporadic cases have been reported [40] . The average age of onset for MAPT mutation carriers is 45-65 years [30, 41] . Penetrance is age-dependent, approaching 100% after age 65 years. The MAPT phenotype is highly variable, even within families. bvFTD with disinhibition is the most common phenotype, but atypical parkinsonism including corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), memory loss, and PPA have been reported [40] . Motor neuron disease (MND) is not a feature of MAPT-related FTD. Imaging usually reveals symmetrical frontotemporal atrophy and hypometobolism [30] . Tau pathology is found in all cases with a MAPT mutation.
GRN, also on chromosome 17 [42, 43] , has at least 80 reported mutations. GRN accounts for about a quarter of autosomal dominant FTD and up to 5% of apparent sporadic cases [3] . GRN appears to be nearly 100% penetrant by age 80 years. Age of onset is typically somewhat older than that of MAPT, ranging from 35 to 89 years [30] . Clinical phenotypes show significant inter-and intra-familial variability. bvFTD with apathy rather than disinhibition [43] is the most common presentation, but nfPPA and CBS are not infrequent [30] . Early memory loss and hallucinations can be present. MND is not a part of this syndrome. GRN mutation carriers have more autoimmune disease than non-carriers [44, 45] . Imaging of GRN mutation carriers typically shows asymmetric atrophy involving the frontal, temporal, and parietal lobes [30] . GRN mutation carriers invariably have TDP-43 pathology on brain autopsy [46] .
Mutations in C9orf72 are due to intronic expansions of a hexanucleotide (GGG GCC ) repeat. Not only are C9orf72 expansions responsible for about 30% of familial FTD, but also up to 50% of familial amyotrophic lateral sclerosis (ALS), and about 88% of cases with symptoms of both FTD and ALS [47] . C9orf72 expansions account for about 6% of apparent sporadic FTD [48] . C9orf72-associated FTD phenotypes are extremely variable. The most common presentations are bvFTD, ALS, FTD/ALS, parkinsonism, ataxia, chorea, and psychosis with hallucinations and delusions. Psychosis can occur any time during the disease, even as a prodromal symptom [49] , and has been reported in 28-56% of cases [50] . C9orf72 is thought to be less than 100% penetrant, but approximately 50% of carriers are affected by age 58 years [48, 51] and 90% by age 70 years [30] . PPA is a rarer presentation than with GRN or MAPT [50] . Like GRN, C9orf72 is associated with an increased risk of autoimmune disease [45] . Imaging for C9orf72 is more variable, but usually symmetrical and cerebellar atrophy can be a feature [52] .
C9orf72 presents many unknowns. The repeat expansion is highly unstable with pathogenic repeat numbers ranging from approximately 30 to thousands, whereas normal alleles have less than 20 repeats (most commonly 2, 5, and 8 repeat alleles). The pathogenicity of 20-30 repeats is questionable [53] . Whether phenotype or age of onset correlates with repeat number is debatable, with most studies reporting no correlation [54, 55] , although one study showed correlation with disease duration [51] . Hypermethylation may influence repeat length correlation [36] . However, the number of repeats can undergo somatic expansion, with the number found in blood differing from that in the brain [50] . The cerebellar repeat number may be the best indication of age of onset [56] . Ambiguity about anticipation also exists [48, 57] .
Genetic Modifiers
GWAS and NGS studies have identified several genetic modifiers of FTD. The most significant genetic risk factor for TDP-43 pathology are variants in TMEM106B (transmembrane protein 106B gene), which were identified in a GWAS of frontotemporal lobar degeneration (FTLD)-TDP pathology-confirmed cases and GRN mutation carriers [58] . The minor alleles of TMEM106B risk single nucleotide polymorphisms (SNPs) may be protective in GRN mutation carriers, suggesting genotyping for these SNPs may be important clinically in helping to predict penetrance. TMEM106B SNPs also appear to modify the C9orf72 phenotype and cause later onset of dementia phenotypes [59] . The mechanism by which TMEM106B variants modulate risk of TDP-43 pathology is unknown, but multiple lines of evidence suggest effects on lysosomal function [59] .
A polymorphism in GRN was associated with risk of AD and Parkinson's disease but not FTD [60] . A polymorphism in MAPT was associated with risk of FTD, AD, and Lewy body dementia [38, 39, 61] . Additionally, a homozygous mutation in GRN has been found to cause adult ceroid lipofuscinosis, a lysosomal storage disease [62] . The pathogenic role of C9orf72 has been questioned since expansions have been found in 0.6% of controls. Some researchers hypothesize the need for a second hit in another gene before disease is caused. In fact, C9orf72 expansions have been found in conjunction with mutations in other genes such as GRN [48] and TBK1 [63] , and SQSTM1 [64] . The fact that C9orf72 and the great majority of the rarer FTD genes (other than CHMP2B) have been implicated in both ALS and FTD indicates that the two diseases are genetically and pathologically related.
Genetic and Genomic Technology in the Study of AD and FTD
Technological advances in molecular biology have changed the field of molecular diagnosis. Traditionally, each gene or mutation was tested individually in a targeted manner; the molecular method used was dependent of the type of mutation being tested and the diagnostic question. Targeted methods include Sanger sequencing for one or more exons, restriction fragment length polymorphism assay to target single nucleotides, or a hybridization method for small numbers of mutations. Sanger sequencing of entire genes, generally one exon at a time, was the standard method of sequencing and was relatively slow and labor intensive. The advent of massively parallel sequencing or NGS, which evaluates many genes at the same time, revolutionized testing. NGS can be performed by targeting a panel of genes, a whole exome, or a whole genome. The large increase in efficiency of scale for providing information rapidly demonstrated NGS' power for diagnostic purposes, particularly when multiple genes are associated with a clinical phenotype. Sanger sequencing is still a cost-effective approach for targeted analysis, such as a known familial mutation or for confirmation of a mutation found through NGS. However, not all mutational mechanisms lend themselves to standard NGS methods, especially repeat expansion diseases with large repeated sequences such as C9orf72. For this mutational mechanism, a targeted analysis using repeat-primed PCR is typically used. In addition, large deletions or copy number variations are not reliably detected by all NGS methods. For these, targeted methods or array-based methods are needed.
Genetic testing for a disease phenotype, such as FTD and AD, requires knowledge of the associated genes and the types of causative mutations to ensure the testing method(s) selected will detect the relevant mutations allowing for clinical interpretation. Each genetic test has limitations which must be considered in the ordering and interpretation of genetic testing results.
Clinical Genetic Counseling and Testing Issues for AD and FTD Produced by Next-Generation Sequencing
Genotype-phenotype correlation studies highlight how the phenotypes of dementia, particularly in the presence of a C9orf72 expansion, can overlap thereby complicating diagnosis and prognosis. Although symptomatic treatment may not change, establishing a correct diagnosis is critical for determining eligibility for clinical trials and for genetic counseling of family members. Since the great majority of AD and FTD cases are not due to a definitive genetic etiology, genetic testing should not be considered standard of care. However, in the presence of a strong autosomal dominant family history or particular clinical presentation (e.g., very early onset or FTD/ALS), the option for genetic testing should be raised by the clinician [65] . Importantly, regardless of family history, all patients should be offered genetic counseling to answer any questions or concerns that the family may have. For many of these families, learning about their particular inheritance risk can lower anxiety and actually reduce the amount of testing ordered. Standard diagnostic procedures now include biomarker testing to distinguish AD from other dementias, including amyloid imaging and measurement of β-amyloid and tau in cerebrospinal fluid (CSF). However, not all patients have access to these procedures and, even when they are performed, results may be inconclusive. Genetic testing potentially can clarify diagnosis. When deciding on the most efficacious course for genetic testing, diagnostic confidence, family history, and ability to pay for testing must be considered [66] . Diagnostic certainty may be improved by biomarker measurement but may not be an alternative because insurance will not cover it or it may not be available at the diagnostic site. A thorough family history of at least three generations is essential for establishing whether an autosomal family history is present and for clarifying diagnosis. For example, a patient who presents with memory complaints and a family history of an early-onset amnestic disorder would strengthen a diagnosis of AD as opposed to a family history of a dementia with behavioral onset, which would hint at FTD. An even stronger indication of FTD would be a relative with ALS. Previous genetic testing on family members should be gathered. However, clinical testing performed before 2011 would have missed mutations in C9orf72 as well as in many of the rarer genes that are now associated with FTD. Ideally these families should be recontacted and offered testing. However, the original patient may have died, and contact may have been lost. Additionally, patients may have been tested under a research protocol that did not permit re-contact.
Before the advent of NGS technology, single gene testing or disease-specific sequencing panels (several genes sequenced at the same time) were performed based on probable diagnosis and family history. For financial reasons, testing frequently was performed sequentially. For example, with an autosomal dominant family history of EOAD, PSEN1 would be tested first, then APP, then PSEN2. If these genes were negative, FTD genes might be tested. NGS allows for the simultaneous analysis of many genes at a lower cost per gene. However, NGS raises new issues, one of which is the generation of indeterminate results at an increased rate compared with older single-gene technologies. Genetic variants identified by sequence analysis must be reviewed to determine their pathogenicity. A guideline for the interpretation and classification of sequence variants was published jointly by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. The guideline uses a risk score to classify variants into five categories based on available evidence: pathogenic, likely pathogenic, likely benign, benign, and variant of uncertain significance (VUS) [67] . A VUS is a variant for which there is not enough evidence to classify it as pathogenic or as benign. The more genes that are tested, the more likely it is to find one or more VUS. Although polymorphisms were also revealed when Sanger sequencing was the common methodology, the greater number of genes analyzed in NGS panels or WES increases the risk of detecting one or more VUS. While the significance of a VUS may be clarified by testing additional family members, family members are not always available. Therefore, VUS and any unclear genetic analysis result can raise genetic counseling dilemmas. Finding another definitive pathogenic mutation in a disease-associated gene reduces, but does not eliminate, the chance that a VUS is associated with the disease in the family. This complication stems from the rare discovery that mutations in two different genes can co-exist in the same individual. Examples of this include C9orf72/GRN, C9orf72/MAPT, C9orf72/SQST1, C9orf72/TARDP [56, 68, 69] .
A dementia gene panel NGS test may be ordered for a patient with an autosomal dominant family history. Testing laboratories do not necessarily include the same genes on their panels. Because testing techniques are different, C9orf72 may not be included on a panel and should be ordered separately. A suggested testing workflow algorithm (Fig. 1) is to first test for an expansion in C9orf72 and then, if negative, reflex to an NGS gene panel possibly followed by duplication/deletion (dup/del) testing of specific genes such as APP. Typically, if an expansion is discovered, further testing is cancelled. This stepwise testing algorithm is the most cost-effective process; however, by not running the full gene panel, a second mutation in another gene may go undiscovered. Likewise, running a smaller, disease-specific panel (e.g., a panel containing only AD-related genes) may fail to reveal an unexpected gene. Therefore, in clinical settings, patients should be counseled about the benefits and limitations of each type of test. When possible (insurance coverage or ability to pay), patients should be given the option of selecting a complete panel. Unfortunately, not all laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA'88) perform all relevant tests. The clinical presentation and specific family history may help to dictate what testing to pursue, but even with a thorough neurological workup, varying genotype-phenotype associations as well as disease phenocopies can lead to unexpected results. Sha et al. [70] reported finding a C9orf72 expansion in a 64-year-old man with a positive amyloid scan and diagnosis of AD.
A strong family history suggesting an inherited disorder is an important trigger for ordering genetic testing; however, testing should also be considered in apparent sporadic cases since sporadic mutations, particularly in C9orf72, have been reported [71] . Presenting the possibility of a genetic etiology may provoke unnecessary worry. Clinicians must balance possible unwarranted anxiety with the patient's right to elect whether to pursue testing. The specific disease presentation may clarify whether to pursue testing (e.g., testing would be inappropriate for a sporadic case of classic LOAD, but relevant for ALS). Genetic counseling can be offered to assist patients and their families with the decision to test.
Conclusions and Best Practice for Genetic Testing for AD and FTD
Determining the appropriate algorithm for diagnostic genetic testing is dependent on clinical phenotype, biomarker testing, and family history. A three-generational family history should be taken which includes onset symptoms and ages of any neurological or psychiatric disorder and ages of death. Based on this information, the likelihood of finding a mutation can be assessed [65, 72] . Additionally, any prior genetic testing or autopsy within the family should be documented, preferably with written records. The existence of a known pathogenic mutation in a family member allows single mutation targeted analysis. Availability of an affected relative's autopsy may guide testing since underlying pathology correlates well with gene mutation. However, pathological techniques have changed significantly over the past few decades. Prior to 2006, TDP-43 staining did not exist [73] . At that time, non-tau ubiquitin-positive FTD was reported as dementia lacking distinctive histology. Nevertheless, a pathological diagnosis of AD in a family with multiple family members with similar phenotype to the proband will enable genetic testing to focus on AD-associated genes, whereas a report of a tauopathy might point to testing for MAPT mutations and TDP-43 pathology would suggest targeting GRN and C9orf72 and other genes. After evaluating the available information, the algorithm for genetic testing can be formulated (Fig. 1) . As already suggested, the clinician should strive to narrow the number of genes being tested. WES should not be ordered unless, in the presence of a definitive family history or unusual clinical presentation, an NGS panel is negative (Fig. 1) . Otherwise, WES is unlikely to reveal a causal mutation and may add to uncertainty with the identification of one or more VUS. Unlike childhood diseases, parents and older relatives of patients with adult-onset neurodegenerative diseases are often unavailable for testing to help clarify the significance of VUS. In some cases, exome sequencing can help uncover a different disease diagnosis than that which was initially suggested based on presenting phenotype due to the extensive clinical overlap of neurodegenerative disease phenotypes.
All families should be offered genetic counseling to inform them about the reasons for and implications of testing, and the benefits and limitations of different avenues of testing, and to guide decision making. Patients must be informed about whether their insurance will cover testing and, if not, about the cost of the different tests.
As data are collected over time in shared databases such as ExAC (Exome Aggregation Consortium; http://exac. broad insti tute.org), variants now classified as uncertain may be reclassified. Additionally, more information on the penetrance of different variants and the existence of genetic phenomena such as anticipation will be available. Even now, well-established autosomal dominant genes such as PSEN2, GRN, and C9orf72 are known to be less than fully penetrant. Large research studies such as DIAN (Dominantly Inherited Alzheimer's Network), LEFFTDS (Longitudinal Evaluation of Familial Frontotemporal Dementia), and ARTFL (Advancing Research and Treatment for Frontotemporal Lobar Degeneration) will add to existing penetrance data. Information from these large studies combined with experience gained from increasing clinical application of NGS technologies for the diagnosis and counseling of neurodegenerative disease patients will undoubtedly improve the ability to counsel patients and families about their genetic risks and to navigate the many options for genetic testing.
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